1. Benefits of engaging with the
Specialised Services
Commissioning Innovation
Fund (SSCIF)
Andrew Jones, Senior Medical Science Manager| Bristol-Myers Squibb
Bernie Stocks, Associate Director, Innovation Adoption, Specialised Services |
NHS England

2. Specialised Services Innovation
Bernie Stocks
13 June 2013

3. Specialised Services Innovation ‘job card’
3
IHW:
Create an
innovation
fund
Legal Duty to
promote
research and
innovation
NHS
England
Ambition:
equity&
excellence-
specialised
care
The
Mandate
The Carter
Review
http://www.dh.gov.uk/pro
d_consum_dh/groups/dh
_digitalassets/document
s/digitalasset/dh_131784
.pdf
http://www.dh.gov.uk/prod_consu
m_dh/groups/dh_digitalassets/@
dh/@en/documents/digitalasset/d
h_4135216.pdf
http://mandate.dh.gov.uk/
NHS | ABPI | 13 04 13

4. 4
Specialised Services
Commissioning Innovation
Fund (SSCIF)

5. SSCIF
For innovations:
Which are new to NHS specialised services or applied in a way that is new
to NHS specialised services
That have shown promise of delivering an improvement in the quality or
cost and affordability of service delivery
Which have a clearly defined value proposition and, if a service or product,
have reached entry levels of safety ready for evaluation in clinical practice.
SSCIF Evaluation Projects
Will be rapid, typically ranging from six to 18 months
Can involve collaboration between commissioners, clinicians, patients,
innovators and the commercial sector
5

6. SSCIF – Prime Objective
• To generate missing data and information on the impact of the innovation on:
 Quality,
 Cost and affordability and
 NHS activity levels
…which can be used to inform commissioning policy
• By rapidly evaluation in a clinical, healthcare service setting, innovative
models of care, pathways, approaches, devices, technologies, products and
medicines with the potential to deliver high impact change for NHS
specialised services
6

7. • Idea
• Design
• Prototype
Invention
• Safety Testing
• Effectiveness Evaluation
• Effectiveness Testing
• Innovation Implementation
• Early Implementation
• Procurement
• Secondary Implementation
Adoption
• Voluntary Diffusion
• Advisory Diffusion
• Mandatory Diffusion
Diffusion
Focus
of
SSCIF
SSCIF Focus within the stages of Innovation

8. SSCIF will test innovations at these stages:
• Proof of ConceptEffectiveness
Evaluation
• Proof of Impact
Effectiveness
Testing
• Post launch evaluation
Innovation
Implementation
• Early adopter
implementation
Early
Implementation
Adoption

9. SSCIF - Benefits
• Creation of an evidence base for use in national commissioning decisions
which will result in rapid, widespread adoption of proven innovations in the
NHS.
• Earlier access to innovative care for patients.
• Increased value for money to the NHS.
• Increase knowledge of offer and impact of individual innovations/products
9

10. Process
decision
Simple on-line Step 1: Self-Assessment
Step 3: Detailed Submission (Table top expert review
Step 2: Qualifying Submission Form (CRG Chair reviews)

11. Process
• Open to healthcare staff, manufacturers, clinicians, researchers, patient
groups and commissioners.
• Submissions can be made anyone at Steps 1 and 2, but by Step 3, a
practising Lead Healthcare Practitioner employed by a healthcare
organisation that supports the generation of wealth in the UK will need to
sponsor and agree to lead the project.
• Manufacturers and others can form alliances with health staff to do this.
Medical Directors of the Healthcare Lead’s organisation will need to endorse
the submission.

12. Funded Projects - documents and requirements
decisionFunded SSCIF Evaluation Projects will have a Service Level Agreement
with a contract schedule taken from the Step 3: Detailed Submission
Form detailing the key activities, key milestones, intended outcomes and
key performance indicators.
Lead Applicants will be provided with sample templates for:
 A project initiation document
 A protocol for local ethical approval
 Informed Consent and patient participation
 Data set for Patient Information Leaflets
 Headings for final report including final products, factors for success
etc.

13. SSCIF Next Steps

14. Innovation Health and Wealth
• UK Plan for Growth March 2011
– Challenged NHS CE to review adoption and diffusion of
innovation
• Prompted the NHS CE Review
– Asked major stakeholders what might be done to
accelerate the spread of innovations in the NHS
– Consultation across NHS, Government, Industry,
Academia and Patient Groups
– 310 responses received; 28% from industry (Incl Med Tech)
– 17% of respondents identified the need for innovation
funds (including a specific fund for Specialised Services)
• Resulted in IHW (Dec 2011)
– 31 Actions to drive the adoption and diffusion of innovation

15. Reason for the SSCIF
• Many innovations with promise available to the NHS
– But often languishing at a local/regional level
– No widespread uptake due to lack of commissioning
evidence
• Evidence Generation in Specialised Services often
difficult
– Low volume
– Hard to achieve levels of evidence similar to those
generated by RCTs
– Even data (incl. RCTs) sufficient for MA are often not
enough to convince commissioners of the innovation’s
value in clinical practice

16. Ethos of the SSCIF
• Aid accelerated adoption and diffusion of transformational
innovations
– Generate evidence on the value of promising innovations
that are available for use in the NHS
– To enable evidence based commissioning decisions to be made
– Make use of New Structure
– National commissioning decisions for specialised services
– Set a paradigm for adoption and diffusion of innovation in a
clinically led fashion

17. Another Hurdle?
• No!!
• In the past
– Drugs not considered by NICE or not recommended due to
lack of evidence
– Commissioning considered independently by 10 SCGs
– Each following a different process (rarely evidence generating)
– Potential for 10 different decisions
• Now
– 1 National decision on specialised services commissioning
– Must be based on robust evidence
– How can this be obtained if not a NICE topic or not recommended
due to lack of evidence
• The SSCIF is a real opportunity

18. Silo Busting
• SSCIF Evaluation Projects will:
– Look at complete patient pathway, taking into account:
– Impact of the innovation on outcomes; and
– Cost and efficiency; and
– Activity levels
across all parts of the pathway
– Consider:
– Societal Impacts
– Gaps in service provision (degree of unmet need)
– Generate evidence to fill data gaps that are preventing
commissioning
– Data gaps on effectiveness and costs in the NHS

19. Real Opportunity for Partnership
• The SSCIF aims to generate evidence that is:
– Is needed by NHS England for national commissioning decisions
in the new structure
– Could benefit the manufacturer once generated
• Therefore generation of evidence should be funded jointly
– NHS England has set up a fund (SSCIF) to generate the
information it needs for all innovations
– Manufacturers should not rely wholly on NHS funding to generate
data on their products (State Aid)
– So for commercial applications to the SSCIF, the evaluation
projects will need to be jointly funded by the applicant and by the
SSCIF

20. Unrivalled potential
• A successful evaluation project will result in
– National Commissioning Policy
– potentially a National commissioning decision.
– This is unlike anything seen before in specialised services
• The partnership ethos will extend to commissioning
arrangements post SSCIF evaluation
– Exclusivity terms
– Discounted purchase price